SONUS REPORTS TOCOSOL PACLITAXEL DATA

A A

Sonus Pharmaceuticals has reported data from an ongoing Phase II trial in metastatic breast cancer as well as an update on the safety and tolerability of Tocosol Paclitaxel for all patients treated to date in the Phase II program.

Tocosol Paclitaxel is a novel, ready-to-use paclitaxel formulation that is cremaphor-free, which allows for shorter infusion times (15 minutes) and may improve patient tolerability and reduce treatment-limiting side-effects. It delivers nearly 70 percent higher exposure to unbound paclitaxel than an equivalent dose of Taxol. When used as single-agent therapy at doses of 100 or 120 mg/m2 weekly, Tocosol Paclitaxel has shown promising antitumor response rates, time-to-progression and survival duration.